Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)

Long-Term Efficacy of Vismodegib After its Withdrawal and Patients’ Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI)

Abstract Introduction Although non-melanoma skin cancers (NMSCs) are associated with a very low mortality risk, they have been reported to have a major impact on patients’ health-related quality of life (HRQoL). Vismodegib is a therapy for patients who are affected by locally advanced basal cell car...

Full description

Bibliographic Details
Main Authors: Alessia Villani, Matteo Megna, Gabriella Fabbrocini, Milena Cappello, Maria Antonietta Luciano, Claudia Costa, Massimiliano Scalvenzi
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-09-01
Series:Dermatology and Therapy
Subjects:
Basal cell carcinoma
DLQI
Drug withdrawal
Quality of life
Skin cancer
Vismodegib
Online Access:http://link.springer.com/article/10.1007/s13555-019-00323-4

Internet

http://link.springer.com/article/10.1007/s13555-019-00323-4

Similar Items